ENOV · Enovis
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $24.00
Note written ·
Price against the kill line
15.3% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $24.00, on record since 10 November 2026. The shares are up 11.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $24.00, under the $24.42 close of 4 November 2026 before the third-quarter report, which would erase the whole post-report gain. Full-year 2026 organic growth below about 5%, or free-cash-flow conversion under 25%, would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 2 October 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 559
- Revenue, change on a year (%)
- +1.8
- Gross margin (%)
- 60.8
- Operating margin (%)
- 0.6
- Free cash flow, four quarters ($M)
- 69.6
- Net cash, cash less debt ($M)
- −1,245
- Enterprise value to sales (×)
- 1.2
- Free-cash-flow yield (%)
- 4.4
All filed numbers
What Enovis reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 559 | +1.8 | 60.8 | 0.6 |
| first filed | 583 | +3.2 | 61.6 | 3.0 |
| first filed | 589 | +5.4 | 62.0 | 1.1 |
| first filed | 576 | +2.6 | 60.7 | −87.2 |
| first filed | 549 | +8.6 | 59.9 | −101.7 |
| first filed | 565 | +7.5 | 59.3 | −3.0 |
| Pre-tax income ($M) | −0.5 |
| Net income ($M) four quarters: −527 | 3.1 |
| Diluted shares, change on a year (%) against the quarter to 3 October 2025 | +2.3 |
| Operating cash flow ($M) | 259 |
| Capital spending ($M) | 190 |
| Free cash flow ($M) | 69.6 |
| Cash and short-term investments ($M) | 13.0 |
| Debt ($M) long-term debt | 1,258 |
| Net cash, cash less debt ($M) | −1,245 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 428 |
| Inventory ($M) | 620 |
| Shareholders' equity ($M) | 1,493 |
| Market value ($M) | 1,597 |
| Enterprise value, market value plus net debt ($M) | 2,842 |
| Enterprise value to sales (×) | 1.2 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.1 |
| Free-cash-flow yield (%) | 4.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 20.3% of shares outstanding sold short, 8.7 days of average trading to cover, +10.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $600K | $0 |
| 12 monthsfrom | $912K | $45K |
The thesis
Enovis Corporation's shares are modestly more likely than not to beat the S&P 500 over the next three months. The reason is that the orthopedic turnaround passed its third-quarter test on 5 November 2026, with 4.6% organic growth, raised earnings guidance and a $200 million buyback. The fourth-quarter report, expected in late February 2027, settles whether full-year organic growth of about 5% and free-cash-flow conversion of at least 25% are delivered.
The shares closed at $28.55 on 11 November 2026. They closed at $24.42 on 4 November 2026, the session before the report, and $28.62 on 5 November 2026, so the post-report gain has held for five sessions. The market now prices in a company that hits its narrowed 2026 range: consensus sales of $2.339 billion sat near the middle of the $2.32–$2.35 billion guide on 5 November 2026 (Benzinga).
Insiders are still buying after the rally. Director Sharon Wienbar bought 1,831 shares at an average $27.26 between 6 November 2026 and 9 November 2026 (SEC Form 4 filed 10 November 2026). That adds to purchases by the chief executive and the chief administrative officer near $19 to $20 in early September.
Bullish and bearish views on Enovis Corporation
The bull case on Enovis Corporation (ENOV), in brief: third quarter landed inside guidance. The bear case: revenue guidance narrowed rather than raised.
Bull case
- Third quarter landed inside guidance. Net sales were $558.7 million for the quarter ended 2 October 2026, up 1.8% reported and 4.6% organic (Form 8-K, 5 November 2026). Reconstructive implants grew 6.3% organically and International Reconstructive 7.8%.
- Earnings beat and guidance rose. Adjusted earnings per share (EPS) were $0.88, against $0.75 a year earlier and a $0.77 consensus estimate (Benzinga, 5 November 2026). Enovis raised 2026 adjusted EPS guidance to $3.58–$3.79 from $3.52–$3.73, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guidance to $428–$438 million from $425–$435 million.
- Buyback doubled in size. The board approved up to $200 million of repurchases, replacing the prior $100 million program (5 November 2026 release).
- Analysts raised targets after the report. BTIG's target went to $42 from $36 and Needham's to $38 from $34 on 5 November 2026. Wells Fargo's target rose to $37 and Evercore ISI's to $33 on 6 November 2026, all with positive ratings.
- Insiders bought at two price levels. CEO Damien McDonald bought 13,035 shares at $19.15 on 4 September 2026, and Chief Administrative Officer Oliver Engert bought 10,258 shares across 2 September to 4 September 2026 (SEC Form 4 filings). A director added shares near $27 in November.
Bear case
- Revenue guidance narrowed rather than raised. Enovis cut the top of its 2026 sales range to $2.35 billion and lifted the bottom to $2.32 billion, from $2.31–$2.37 billion, and set organic growth at about 5% from 4–6% (5 November 2026).
- GAAP earnings are close to zero. Third-quarter operating income was $3.4 million and GAAP EPS from continuing operations was $0.02 (Form 8-K, 5 November 2026). The valuation case rests on adjusted figures.
- Cash is thin against debt. Enovis held $13.0 million of cash and $1,258.3 million of total debt at 2 October 2026. The eCential Robotics purchase calls for about €176 million of closing cash (1 September 2026 announcement), so the buyback and the deal draw on the same funds.
- Bracing still lags implants. Prevention & Recovery sales fell 1.9% reported while rising 3.0% organically in the third quarter, and International Prevention & Recovery fell 0.7% organically.
- One target moved lower. Canaccord Genuity cut its target to $42 from $45 on 6 November 2026 while keeping a Buy rating.
Price setup
The last close was $28.55 on 11 November 2026, above the 50-day moving average of $20.21 and the 200-day moving average of $23.18 (adjusted daily closes, as of 11 November 2026). The shares are up 11.3% over three months, against a $25.66 close on 13 August 2026.
The 52-week closing low was $17.43 on 8 October 2026, after the eCential offer and before the report. The 52-week intraday high is $32.41, set on 12 November 2025; the last close is 11.9% below it. That high is the next price the shares would have to reclaim to show the turnaround fully re-rated.
The case turns on the $24.42 close of 4 November 2026, the last session before the report. Closes have held between $27.16 and $28.62 in the five sessions since, so the market has kept the report's gain rather than fading it.
Catalysts ahead
- ~31 December 2026 (est.): Expected closing of the eCential Robotics acquisition, after French works council consultation and regulatory approvals. Closing sets the timing of the about €176 million cash outlay against $13.0 million of quarter-end cash, and starts the projected 2027 adjusted EBITDA-margin drag of about 1 percentage point.
- ~25 February 2027 (est.): Fourth-quarter and full-year 2026 results, with first 2027 guidance. Shows whether full-year organic growth of about 5% and free-cash-flow conversion of at least 25% were delivered, and how much margin the eCential deal costs in 2027.
What would change the view
A daily close below $24.00, under the $24.42 close of 4 November 2026 before the third-quarter report, which would erase the whole post-report gain. Full-year 2026 organic growth below about 5%, or free-cash-flow conversion under 25%, would also prove the call wrong.
The risks this note tracks, each with what would confirm it:
- Full-year growth or cash conversion falls short of the updated 2026 guidance. Confirmed by: full-year 2026 organic growth below about 5%, or free-cash-flow conversion under 25%, in the fourth-quarter report.
- The buyback and the eCential purchase raise debt while cash is thin. Confirmed by: total debt rising above the $1,258.3 million reported at 2 October 2026 in the next filing, alongside repurchases.
- The eCential acquisition pushes margin recovery out further than forecast. Confirmed by: a 2027 adjusted EBITDA-margin headwind worse than the net 1 percentage point Enovis projected on 1 September 2026, in first 2027 guidance.
- Prevention & Recovery bracing keeps dragging on total growth. Confirmed by: Prevention & Recovery organic growth below the 3.0% reported for the third quarter of 2026, in the fourth-quarter report.
What it trades with
Enovis sits in the medtech group with Vericel, OrthoPediatrics, AxoGen and Glaukos. Only OrthoPediatrics shares the orthopedic implant exposure. The shares respond to elective joint-replacement volumes, Enovis's own leverage and the eCential deal more than to any group trend: the 5 November 2026 report alone moved the close from $24.42 to $28.62. A sector-wide slowdown in elective orthopedic procedures would hit the case regardless of how the peer group trades.
The evidence, claim by claim (8)
- Third-quarter 2026 net sales were $558.7 million, up 1.8% reported and 4.6% organic; Reconstructive grew 6.3% organically and Prevention & Recovery 3.0% organically. Enovis Form 8-K, third-quarter 2026 earnings release · as of
- Third-quarter adjusted EPS was $0.88, against $0.75 a year earlier and a $0.77 consensus estimate; GAAP EPS from continuing operations was $0.02. Enovis Form 8-K; Benzinga earnings report · as of
- 2026 guidance: revenue $2.32–$2.35 billion (from $2.31–$2.37 billion), organic growth about 5% (from 4–6%), adjusted EBITDA $428–$438 million, adjusted EPS $3.58–$3.79, free-cash-flow conversion 25% or higher. Enovis Form 8-K, third-quarter 2026 earnings release · as of
- The board authorized up to $200 million of share repurchases, replacing the prior $100 million program. Enovis Form 8-K, third-quarter 2026 earnings release · as of
- Cash was $13.0 million and total debt $1,258.3 million at quarter-end. Enovis Form 8-K, third-quarter 2026 earnings release · as of
- BTIG raised its target to $42 from $36 and Needham to $38 from $34; Wells Fargo raised to $37, Evercore ISI to $33, and Canaccord Genuity lowered to $42 from $45. Benzinga analyst-rating reports · as of
- Director Sharon Wienbar bought 1,831 shares in the open market at $26.98–$27.55 (average $27.26) between 6 November 2026 and 9 November 2026. SEC Form 4 filed 10 November 2026 · as of
- CEO Damien McDonald bought 13,035 shares at $19.15 on 4 September 2026; CAO Oliver Engert bought 7,598 shares on 2 September to 3 September 2026 and 2,660 shares on 4 September 2026. SEC Form 4 filings, 4 September 2026 and 8 September 2026 · as of
Sources
- Enovis CORP - Form 8-K - FY2026 · sec.gov
- Enovis CORP - Form 10-Q - FY2026 · sec.gov
- Enovis to acquire surgical robotics company for $180M · beckersspine.com
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
See also · stocks to watch